Care/of Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

Is Care/of Legit? A Structured Evaluation

Care/of is a legal, registered business that sells dietary supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA). It is not a pharmacy, does not require a prescription, and does not employ prescribers. Whether the brand is "legit" depends on the question you are asking. The company exists, ships real products, and is owned by a major pharmaceutical corporation. Whether its personalization claims are clinically meaningful is a separate, harder question.

Corporate Structure and Regulatory Standing

Bayer AG acquired Care/of in August 2020. The brand operates as a consumer-health subsidiary. Products are manufactured under the Current Good Manufacturing Practice (cGMP) regulations enforced by the FDA for dietary supplements under 21 CFR Part 111 (FDA cGMP for dietary supplements). Those regulations govern manufacturing quality but do not require the manufacturer to prove a supplement works before selling it.

The Federal Trade Commission (FTC) has repeatedly warned the supplement industry that unsubstantiated health claims violate Section 5 of the FTC Act. Care/of's marketing language ("We recommend what's right for you") is phrased as personalization rather than a direct disease claim, keeping it within DSHEA's gray zone.

LegitScript and Pharmacy Status

LegitScript certifies online pharmacies and telehealth platforms that dispense prescription drugs. Care/of does not appear on LegitScript's approved pharmacy list because it does not dispense Rx medications. If you encounter a site claiming to sell "prescription Care/of products," that is not the brand's core model and deserves independent scrutiny.

BBB Complaints: What They Actually Say

The Better Business Bureau profile for Care/of (filed under Ritual/Care/of) showed a rating of B as of July 2025, with closed complaints concentrated in two categories: difficulty canceling subscriptions and charges after cancellation requests. These are consumer-protection concerns, not safety signals. The FDA Adverse Event Reporting System (FAERS) does not show a notable cluster of serious adverse event reports specifically attributed to Care/of products, though under-reporting in the supplement space is well documented (FDA FAERS).

How Care/of's Personalization Algorithm Works

Care/of recommends supplements based on a quiz covering diet, lifestyle, health goals, and self-reported symptoms. No lab values are collected. No licensed clinician reviews the output. The algorithm maps quiz answers to a product catalog and generates a recommendation.

What the Algorithm Can and Cannot Do

The quiz can reasonably flag obvious nutritional gaps. A person who reports eating no fish, for example, might get an omega-3 recommendation consistent with broad dietary guidance. That is a low-risk, plausible suggestion. The quiz cannot detect deficiencies that require blood testing, such as vitamin B12, vitamin D, ferritin, or magnesium. A 2020 analysis in JAMA Network Open found that 45% of U.S. Adults took dietary supplements, yet deficiency rates for key micronutrients remained largely unchanged, suggesting that quiz-driven supplementation without lab confirmation may miss the people who need intervention most (Cowan et al., JAMA Network Open, 2020).

No Published Algorithmic Validation

Care/of has not published a peer-reviewed validation study of its recommendation engine. The company's internal blog posts reference "scientific advisors" but do not report sensitivity, specificity, or positive predictive value for any recommendation. By contrast, clinical decision-support tools in evidence-based medicine are expected to report discrimination statistics (C-statistic, AUC) before clinical deployment. The absence of any such publication is a meaningful gap.

The table below summarizes a decision framework for evaluating any DTC supplement personalization service against the standards applied to regulated clinical tools.

| Criterion | Evidence-Based Clinical Standard | Care/of Status | |---|---|---| | Lab confirmation of deficiency | Required before prescribing micronutrients | Not collected | | Algorithm peer review | Published validation study | Not published | | Clinician oversight | Licensed prescriber reviews output | No clinician in loop | | Outcome tracking | Pre/post biomarker measurement | Not offered | | Adverse event reporting | Mandatory MedWatch filing for serious events | DSHEA voluntary only |

Prescribing Data: What Care/of Does and Does Not Collect

The phrase "prescribing data" is a misnomer when applied to Care/of. The brand does not prescribe anything. What it collects is quiz response data, purchase history, and self-reported satisfaction surveys. None of that data constitutes clinical outcomes evidence.

Data Privacy and Third-Party Sharing

Care/of's privacy policy (as reviewed July 2025) states that user data may be shared with Bayer AG and its affiliates, third-party analytics vendors, and advertising partners. The policy is governed by the California Consumer Privacy Act (CCPA) for California residents and by GDPR for EU users. Health-related data collected by supplement companies is not covered by HIPAA because they are not covered entities under 45 CFR Part 160. That means the quiz answers you provide about fatigue, stress, and digestive symptoms do not carry the same legal protections as data you give a physician.

A 2021 BMJ analysis of consumer health app privacy policies found that 79% of health apps shared user data with third parties, often for advertising purposes, and that terms of service were written at a reading level requiring 14 or more years of education (Powell et al., BMJ, 2021). Care/of's policy reflects this industry norm rather than departing from it.

No Outcomes Signal Publication

Between Bayer's 2020 acquisition and July 2025, no peer-reviewed outcomes paper has been published under the Care/of brand name in PubMed-indexed journals. A search of ClinicalTrials.gov using "Care/of" and "Bayer consumer health supplements" returns no registered trials specific to this brand's recommendation algorithm. For comparison, the USPSTF reviewed 52 RCTs before issuing its 2022 vitamin D and calcium supplementation guidance, concluding that evidence was insufficient to recommend routine supplementation for cancer or cardiovascular disease prevention in asymptomatic adults (USPSTF Vitamin D Recommendation, 2021).

Outcomes Signals from the Broader Supplement Literature

Because Care/of offers no brand-specific trial data, the relevant question becomes whether the individual supplements in its catalog have meaningful evidence behind them. The answer is highly product-specific.

Products With Reasonable Evidence

Omega-3 fatty acids. The ASCEND trial (N=15,480) found that omega-3 supplementation reduced the incidence of serious vascular events by 11% in people with diabetes who had no prior cardiovascular disease (P<0.001), though total serious adverse events were similar between groups (Bowman et al., NEJM, 2018). This is a meaningful signal but applies to a specific population, not to everyone who answers a wellness quiz.

Folate. The USPSTF gives a Grade A recommendation for folic acid supplementation (0.4 to 0.8 mg/day) in people who are planning or capable of pregnancy, based on consistent evidence of neural tube defect reduction (USPSTF Folic Acid Recommendation, 2023). Care/of's quiz correctly identifies pregnancy planning as a relevant factor for folate recommendations.

Vitamin D. Despite widespread supplementation, the VITAL trial (N=25,871) found that vitamin D3 (2,000 IU/day) did not significantly reduce the incidence of cancer or major cardiovascular events compared to placebo over a median 5.3 years of follow-up (Manson et al., NEJM, 2019). Recommending vitamin D to everyone regardless of serum 25(OH)D level is not well supported by this evidence.

Products With Weak or No Clinical Evidence

Proprietary "focus" or "energy" blends. Several Care/of products include branded blends of adaptogens, B vitamins, and herbal extracts. No large RCT supports the specific combinations. The Cochrane Collaboration's 2019 review of ginseng for cognitive function found no reliable evidence of benefit in healthy adults (Geng et al., Cochrane, 2010, updated search). Ashwagandha has small trials suggesting modest cortisol reduction, but sample sizes rarely exceed 60 participants and follow-up is typically 8 weeks or less.

Consumer Complaints: Patterns and What They Mean Clinically

Care/of complaints on the BBB, Trustpilot, and Reddit (r/Supplements) cluster into three categories.

Billing and Cancellation

The most common complaint type. Users report difficulty canceling subscriptions, charges after cancellation requests, and challenges reaching customer service. These are consumer-protection issues. The FTC's Negative Option Rule (finalized 2024) requires that canceling a subscription be as easy as signing up. Persistent billing complaints may indicate that Care/of's cancellation flow does not meet this standard.

Product Quality and Ingredient Accuracy

A smaller number of complaints allege that delivered products differed from what was recommended. Third-party testing of supplement products is not mandatory under DSHEA. NSF International and USP certification programs provide independent verification of label accuracy, and Care/of does not prominently advertise NSF or USP certification across its full product line as of July 2025.

Lack of Perceived Benefit

Some consumers report no noticeable change after 2 to 3 months of use. This is not a safety signal. Micronutrient supplementation in people who are not deficient generally produces no measurable symptomatic benefit. The absence of perceived benefit in a self-selected, health-conscious consumer population is expected and consistent with the VITAL and ASCEND trial findings described above.

How Care/of Compares to Clinically Supervised Supplementation

The primary distinction between Care/of and a medically supervised supplement protocol is the presence of a licensed clinician and baseline labs.

Lab-Guided vs. Quiz-Guided Dosing

A physician or nurse practitioner ordering a comprehensive metabolic panel, complete blood count, and 25(OH)D level before recommending supplements has objective data. Care/of has quiz answers. For vitamin D specifically, the Endocrine Society's 2024 clinical practice guideline notes that population-level supplementation without testing is reasonable only at doses of 600 to 800 IU/day (the RDA), and that doses above 2,000 IU/day should be guided by serum levels (Endocrine Society Vitamin D Guideline, 2024). Care/of's vitamin D products range up to 2,000 IU, placing some recommendations at the boundary of guideline-supported unsupervised use.

When to See a Clinician Instead

Persistent fatigue, hair loss, muscle weakness, mood changes, and recurrent infections are symptoms that may reflect diagnosable nutritional deficiencies or underlying medical conditions. A 12-question quiz cannot differentiate between iron deficiency anemia (serum ferritin <12 ng/mL), hypothyroidism (TSH >4.5 mIU/L), or simple chronic stress. Treating these with an OTC supplement subscription delays appropriate diagnosis.

The American Academy of Family Physicians recommends against routine multivitamin use for disease prevention in healthy adults, citing insufficient evidence of net benefit (AAFP Preventive Care, 2022).

Regulatory Risk Factors to Watch

FDA Enforcement History

As of July 2025, Care/of has not received an FDA Warning Letter specific to its products. The FDA has, however, issued Warning Letters to other supplement companies making similar "personalized wellness" claims that crossed into disease-claim territory. Care/of's current marketing stays close to structure/function claims ("supports bone health," "supports immune function"), which are permissible under DSHEA with a standard disclaimer. Any shift toward disease-prevention language without substantiation would expose the brand to FTC and FDA action.

State-Level Concerns

No state attorney general action against Care/of was publicly identified as of July 2025. The FTC's 2024 enforcement sweep against subscription billing practices targeted several supplement companies. Care/of's billing complaint pattern places it in a risk category that may attract future enforcement attention.

A Practical Assessment for Consumers Considering Care/of

Care/of products are generally safe at labeled doses for healthy adults. The risk is not toxicity. The risk is spending money on supplements that may not address your actual nutritional status, while delaying a clinical workup that could identify a real deficiency or underlying condition.

If you are curious whether you have a specific deficiency, order a blood test. Vitamin D (25(OH)D), ferritin, B12, and a basic metabolic panel can be ordered through your primary care provider or a direct-to-consumer lab service for roughly $50 to $150. That data is more actionable than any quiz score.

If labs show a true deficiency, supplementation under clinician guidance, with follow-up testing at 90 days, is standard of care. The Endocrine Society defines vitamin D insufficiency as a 25(OH)D level below 20 ng/mL and recommends repletion doses of 1,500 to 2,000 IU/day for adults, with reassessment at 3 months (Holick et al., Journal of Clinical Endocrinology and Metabolism, 2011).